"mild dysglycemia" in type 2 diabetes: To be neglected or not?

Journal of Diabetes and its Complications

Volumn 29, Issue 3, 2015, Pages 451-458

  Monnier, Louis ^a   Colette, Claude ^a   Dejager, Sylvie ^b   Owens, David R ^c  

^a UNIV MONTPELLIER   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Dawn phenomenon; DPP 4 inhibitors; Mild dysglycemia; Post prandial glucose; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN SENSITIZING AGENT; SITAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RISK; DYSGLYCEMIA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE COURSE; METABOLISM; RISK FACTOR;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; POSTPRANDIAL PERIOD; RISK FACTORS;

EID: 84925361908     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.12.004     Document Type: Review

References (75)

1. B. Ahrén, A. Lequizamo Dimas, P. Miossec, S. Saubadu, and R. Aronson Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal M) Diabetes Care 36 2013 2543 2550
2. American Diabetes Association Standards of medical care in diabetes-2014 Diabetes Care 37 Suppl. 1 2014 S14 S80
3. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 37 Suppl. 1 2014 S81 S90
4. R.M. Bergenstal, A.J. Ahmann, T. Bailey, T. Beck, R.W. Beck, and J. Bissen Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: The ambulatory glucose profile (AGP) Diabetes Technology & Therapeutics 15 2013 198 211
5. R.M. Bergenstal, C. Wysham, L. Macconell, J. Malloy, B. Walsh, and P. Yan Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomized trial Lancet 376 2010 431 439
6. G. Boden, X. Chen, and J.L. Urbain Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production Diabetes 45 1996 1044 1050
7. G.B. Bolli, P. De Feo, S. De Cosmo, G. Periello, M.M. Ventura, and F. Calcinaro Demonstration of the dawn phenomenon in normal human volunteers Diabetes 33 1984 1150 1153
8. G.B. Bolli, and J.E. Gerich The «dawn phenomenon» - a common occurrence in both non-insulin dependent and insulin-dependent diabetes mellitus New England Journal of Medicine 310 1984 746 750
9. G.B. Bolli, and D.R. Owens Lixisenatide, a novel GLP-1 receptor agonist: Efficacy, safety and clinical implications for type 2 diabetes Diabetes, Obesity & Metabolism 15 2014 588 601
10. D.E. Bonds, M.E. Miller, R.M. Bergenstal, J.B. Buse, R.P. Byington, and J.A. Cutler The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD Study BMJ 339 2009 b4909
11. M.F. Bouchonville, J.J. Jaghab, E. Duran-Valdez, M. Schrader, and D.S. Shade The effectiveness and risk of programming an insulin pump to counteract the dawn phenomenon in type 1 diabetes Endocrine Practice 2014 10.4158/EP141898.OR
12. M. Brownlee The pathobiology of diabetic complications: A unifying mechanism Diabetes 54 2005 1615 1625
13. M.F. Carroll, and D.S. Schade The dawn phenomenon revisited: Implications for diabetes therapy Endocrine Practice 11 2005 55 64
14. A. Ceriello, K. Esposito, L. Piconi, M.A. Ihnat, J.E. Thorpe, and R. Testa Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients Diabetes 57 2008 1349 1354
15. S. Colagiuri, C.M.Y. Lee, T.Y. Wong, B. Balkau, J.E. Shaw, and K. Borch-Johnsen Glycemic thresholds for diabetes-specific retinopathy. Implications for diagnostic criteria for diabetes Diabetes Care 34 2011 145 150
16. P.E. Cryer Glycemic goals in diabetes: Trade-off between glycemic control and iatrogenic hypoglycemia Diabetes 63 2014 2188 2195
17. P. De Feo, G. Perriello, M.M. Ventura, F. Calcinaro, G. Basta, and C. Lolli Studies on overnight insulin requirements and metabolic clearance rate of insulin in normal and diabetic man: Relevance to the pathogenesis of the dawn phenomenon Diabetologia 29 1986 475 480
18. C.V. De Souza, G.B. Bolli, and V. Fonseca Hypoglycemia, diabetes and cardiovascular events Diabetes Care 33 2010 1389 1394
19. R.A. DeFronzo Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes Diabetes Reviews 5 1997 177 269
20. R.A. DeFronzo, M.N. Hissa, A.J. Garber, J. Luiz Gross, R. Yuyan Duan, and S. Ravichandran The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone Diabetes Care 32 2009 1649 1655
21. D.J. Drucker, and M.A. Nauck The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
22. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, and P.D. Reaven Glucose control and vascular complications in veterans with type 2 diabetes New England Journal of Medicine 360 2009 129 139
23. P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, and O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes New England Journal of Medicine 348 2003 383 393
24. H.C. Gerstein, M.E. Miller, F. Ismael-Beigi, J. Largay, C. McDonald, and H.A. Lachnan Effects of intensive glycaemic control on ischaemic heart disease: Analysis of data from the randomized, controlled ACCORD trial Lancet 384 2014 1936 1941
25. B. Guerci, L. Monnier, P. Serusclat, C. Petit, P. Valensi, and D. Huet Continuous glucose profiles with vildagliptin verus sitagliptin in add-on to metformin: Results from the randomized Optima study Diabetes & Metabolism 38 2012 359 366
26. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction New England Journal of Medicine 339 1998 229 234
27. B. Hirshberg, and I. Raz Impact of the US Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetic drugs Diabetes Care 34 Suppl. 2 2011 S101 S106
28. R.R. Holman, S.K. Paul, M.A. Bethel, D.E. Matthews, and H.A. Neil 10-year follow-up of intensive glucose control in type 2 diabetes New England Journal of Medicine 359 2008 1577 1589
29. R.R. Holman, S.K. Paul, M.A. Bethel, H.A. Neil, and D.R. Matthews Long-term follow-up after tight control of blood pressure in type 2 diabetes New England Journal of Medicine 359 2008 1565 1576
30. R. Huxley, F. Barzi, and M. Woodward Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies BMJ 332 2006 73 78
31. IDF 2012 Clinical Guidelines Task Force Global guideline for type 2 diabetes Diabetes Research and Clinical Practice 2012 10.1016/j.diabres.2012.10.001
32. International Diabetes Federation Guideline Development Group Guideline for management of post-meal glucose in diabetes Diabetes Research and Clinical Practice 103 2014 256 268
33. S.E. Inzucchi, R.M. Bergentstal, J.B. Buse, M. Diamant, E. Ferrannini, and M. Nauck Management of hyperglycaemia in type 2 diabetes; A patient centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 55 2012 1577 1596
34. M. Laakso, and S. Lehto Epidemiology of macrovascular disease in diabetes Diabetes Reviews 5 1997 294 315
35. H.E. Lebovitz Insulin secretagogues: Old and new Diabetes Reviews 7 1999 139 153
36. L.G. Melbin, L. Rydén, M.C. Riddle, J. Probstfied, J. Rosenstock, and R. Diaz Does hypoglycemia increase the risk of cardiovascular events? European Heart Journal 34 2013 3137 3144
37. L. Monnier, and C. Colette Glycemic variability. Should we and can we prevent it? Diabetes Care 31 Suppl. 2 2008 S150 S154
38. L. Monnier, C. Colette, S. Dejager, and D. Owens Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes. Is this of concern? Diabetes Care 36 2013 4057 4062
39. L. Monnier, C. Colette, S. Dejager, and D. Owens Residual dysglycemia when at target HbA1c of 7% (53 mmol/mol) in persons with type 2 diabetes Diabetes Research and Clinical Practice 104 2014 370 375
40. L. Monnier, C. Colette, G. Dunseath, and D.R. Owens The loss of post-prandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes Diabetes Care 30 2007 263 269
41. L. Monnier, C. Colette, and D. Owens Post-prandial glucose in type 2 diabetes: assessment and respective impacts Diabetes Technology & Therapeutics 13 Suppl 1 2011 S25 S32
42. L. Monnier, C. Colette, and D. Owens The glycemic triumvirate and diabetic complications: Is the whole greater than the sum of its component parts? Diabetes Research and Clinical Practice 95 2012 303 311
43. L. Monnier, C. Colette, and D. Owens Basal insulin analogs: From pathophysiology to therapy. What we see, know and try to comprehend Diabetes & Metabolism 39 2013 468 476
44. L. Monnier, M. Hanefeld, O. Schnell, C. Colette, and D. Owens Insulin and atherosclerosis: How are they related? Diabetes & Metabolism 39 2013 111 117
45. L. Monnier, H. Lapinski, and C. Colette Contributions of fasting and post-prandial plasma increments to overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA1c Diabetes Care 26 2003 881 885
46. L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, and J.P. Cristol Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes JAMA 295 2006 1681 1687
47. D.R. Owens, L. Monnier, and G.B. Bolli Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus Diabetes & Metabolism 39 2013 485 496
48. R. Peter, G. Dunseath, S.D. Luzio, and D.R. Owens Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes Diabetes & Metabolism 39 2013 337 342
49. A. Peters Incretin-based therapies: Review of current clinical trial data American Journal of Medicine 123 2010 S28 S37
50. W.H. Polonsky, L. Fisher, C.H. Shikman, D.A. Hinnen, C.G. Parkin, and Z. Jelsovsky Structured self-monitoring of blood glucose significantly reduces A1c levels in poorly controlled, noninsulin-treated type 2 diabetes Diabetes Care 34 2011 262 267
51. K.S. Polonsky, B.D. Given, and C.E. Van Twenty-four profiles and pulsatile patterns of insulin secretion in normal and obese subjects Journal of Clinical Investigation 81 1988 442 448
52. F. Porcelatti, P. Lucidi, G.B. Bolli, and C.G. Fanelli Thirty years of research on the dawn phenomenon: Lessons to optimize blood glucose control in diabetes Diabetes Care 36 2013 3860 3862
53. J. Rosenstock, G.L. Vega, and P. Raskin Effect of intensive diabetes treatment on low-density lipoprotein apolipoprotein B kinetics in type I diabetes Diabetes 37 1988 393 397
54. A. Scheen, and N. Paquot Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes Diabetes & Metabolism 39 2013 179 190
55. M.I. Schmidt, A. Hadji-Georgopoulos, M. Rendell, S. Margolis, and A. Kowarski The dawn phenomenon, an early morning glucose rise: Implications for diabetic intraday blood glucose variation Diabetes Care 4 1981 579 585
56. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, and G.L. Hirshberg Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus New England Journal of Medicine 369 2013 1317 1326
57. Supplementary appendix to: B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, and G.L. Hirshberg Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus New England Journal of Medicine 369 2013 317 1326 (Available at NEJM.org)
58. S.E. Siegelaar, F. Holleman, J.B.L. Hoekstra, and J.H. DeVries Glucose variability; Does it matter? Endocrine Reviews 31 2010 171 182
59. J. Stamler, O. Vaccaro, J.D. Neaton, and D. Wentworth Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Interventional Trial Diabetes Care 16 1993 434 444
60. I.M. Stratton, A.I. Adler, H.A. Neil, D.R. Matthews, S.E. Manley, and C.A. Cull Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study BMJ 321 2000 405 412
61. S. Suh, J.Y. Joung, S.-M. Jin, M.Y. Kim, J.C. Bae, and H.-D. Park Strong correlations between glycaemic variability and total glucose exposure in type 2 diabetes are limited to subjects with a satisfactory glycaemic control Diabetes & Metabolism 40 2014 272 277
62. M.-R. Taskinen Diabetic dyslipidaemia: From basic research to clinical practice Diabetologia 46 2003 733 749
63. The Action to Control Cardiovascular Risk in Diabetes Study Group Effect of intensive glucose lowering in type 2 diabetes New England Journal of Medicine 358 2008 2445 2459
64. The ADVANCE collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes New England Journal of Medicine 358 2008 2560 2572
65. The Diabetes Control and Complications Trial Research group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus New England Journal of Medicine 329 1993 977 986
66. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes New England Journal of Medicine 353 2005 2643 2653
67. The ORIGIN Trial Investigators Basal insulin and cardiovascular and other outcomes in dysglycemia New England Journal of Medicine 367 2012 319 328
68. F.M. Turnbull, C. Abraira, R.J. Anderson, R.P. Byington, J.P. Chalmers, and W.C. Duckworth Intensive glucose and macrovascular outcomes in type 2 diabetes Diabetologia 52 2009 2288 2298
69. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
70. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
71. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
72. UK Prospective Diabetes Study Group 16 Overview of 6 year's therapy for type 2 diabetes: A progressive disease Diabetes 44 1995 1249 1258
73. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, and G.L. Bakris Alogliptin after acute coronary syndrome in patients with type 2 diabetes New England Journal of Medicine 369 2013 1327 1335
74. S. Zoungas, J. Chalmers, T. Ninomiya, Q. Li, M.E. Cooper, and S. Colagiuri Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: Evidence of glycemic thresholds Diabetologia 55 2012 636 643
75. S. Zoungas, A. Patel, J. Chalmers, B.E. de Galan, Q. Li, and M. Biostat Severe hypoglycemia and risks of vascular events and death New England Journal of Medicine 363 2010 1410 1418